Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity
John P. Russell(GlaxoSmithKline (United Kingdom)), Beverley Greenwood–Van Meerveld(University of Oklahoma), Ehsan Mohammadi(University of Oklahoma Health Sciences Center), Allen Oliff(GlaxoSmithKline (United Kingdom)), Michael D. Gershon(Columbia University), Mui Cheung(GlaxoSmithKline (United Kingdom)), Anthony C. Johnson(University of Oklahoma Health Sciences Center), Hilary S. Eidam(GlaxoSmithKline (United Kingdom)), Michael P. DeMartino(GlaxoSmithKline (United Kingdom)), Casey O. Ligon(University of Oklahoma Health Sciences Center), Sanjay Kumar(WuXi AppTec (China)), Chi-Chung Chan(WuXi AppTec (China)), Yuhong Shen(WuXi AppTec (China)), Meenakshi Rao(All India Institute of Medical Sciences Jodhpur)
Cited by 15
Related Papers
Intestinal barrier function in health and gastrointestinal disease
|Neurogastroenterology & Motility|2012|886
Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report
|PEDIATRICS|2010|870
Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome 1 ☆
|Gastroenterology|2004|772
Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel
|Alimentary Pharmacology & Therapeutics|1999|460
Stress and the Microbiota–Gut–Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome
|CNS Neuroscience & Therapeutics|2015|386